<DOC>
	<DOCNO>NCT01979276</DOCNO>
	<brief_summary>This clinical trial subject multiple myeloma return treatment ( relapse ) respond prior treatment ( refractory ) . The study two part , Phase I Phase II . Phase I determine maximum tolerate dose romidepsin combination pomalidomide dexamethasone . The purpose Phase II evaluate effectiveness combine romidepsin pomalidomide dexamethasone . The hypothesis overall response cohort patient treat romidepsin + pomalidomide + dexamethasone 60 percent .</brief_summary>
	<brief_title>Study Pomalidomide , Dexamethasone , Romidepsin Rel/Ref Myeloma</brief_title>
	<detailed_description>This phase I/II study treatment program patient relapse refractory multiple myeloma . Up 48 patient enrol . Phase I follow 3+3 dose escalation design find maximum tolerate dose romidepsin combination pomalidomide dexamethasone . In Phase I , subject receive : - Pomalidomide 4mg daily mouth day 1-21 28-day cycle - Dexamethasone 40mg mouth day 1 , 8 , 15 22 28-day cycle - Romidepsin intravenously ( 9 mg/m2 , 12 mg/m2 , 15 mg/m2 18 mg/m2 ) day 1 15 28-day cycle . Phase II expand number subject MTD arm trial 48 subject enrol . In Phase II , subject subject receive : - Pomalidomide 4mg daily mouth day 1-21 28-day cycle - Dexamethasone 40mg mouth day 1 , 8 , 15 22 28-day cycle - Romidepsin intravenously day 1 15 28-day cycle Maximum Tolerated Dose determine Phase I</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>histologically confirm multiple myeloma . measurable disease define &gt; 0.5 g/dL serum monoclonal protein , &gt; 0.1 g/dL serum free light chain , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) . relapse refractory multiple myeloma define progression disease either prior therapy lack response currently use therapy relapse progressive disease least 3 prior therapeutic treatment regimens multiple myeloma . refractory bortezomib lenalidomide &gt; 18 year time signing informed consent form . life expectancy &gt; 3 month . Karnofsky performance status &gt; 70 % , &gt; 60 % due bony involvement multiple myeloma normal organ marrow function define : 1 . Absolute Neutrophil Count &gt; 1,000 cells/mm3 Phase I , &gt; 750 cells/mm3 Phase II 2 . Platelet Count &gt; 75,000/mm3 Phase I , &gt; 50 , 000/mm3 Phase II 3 . AST/ Serum SGOT &lt; 3.0 x upper limit normal 4 . ALT/ Serum SGPT &lt; 3.0 x upper limit normal 5 . Serum creatinine &lt; 2.0 mg/dL 6 . Serum total bilirubin &lt; 1.5 x upper limit normal Laboratory test result within range : g. Serum potassium ≥ 3.8 mmol/L h. Serum magnesium &gt; 1.8 mg/dL Females child bear potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 1014 day prior start study drug ( ) 24 hour prescribe pomalidomide ( prescription must fill within 7 day ) . Females child bear potential must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start pomalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . Ability understand willingness sign write informed consent document . Subjects nonsecretory Multiple Myeloma ( measurable monoclonal protein plasmacytoma ( ) , free light chain , and/or Mspike blood urine ) . Patients prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless disease free ≥ 3 year . Any known cardiac abnormality : 1 . Congenital long QT syndrome 2 . QTc interval ≥ 480 millisecond 3 . Myocardial infarction within 6 month C1D1 . Subjects history myocardial infarction 6 12 month prior C1D1 asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate 4 . Other significant ECG abnormality include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) 5 . Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV . In subject doubt , subject stress imaging study , abnormal , angiography define whether CAD present 6 . An ECG record screen show evidence cardiac ischemia ( ST depression depression ≥2 mm , measure isoelectric line ST segment ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present 7 . Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition ( see Appendix E ) and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or MRI ; 8 . A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; 9 . Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause ; 10 . Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion ; 11 . Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) Any Known seropositivity active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Any active viral bacterial infection coexist medical problem would significantly increase risk treatment program . Any coexist medical problem laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . ( Lactating female must agree breast feed take pomalidomide . ) Subjects condition , include presence laboratory abnormality , opinion Investigator place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 14 day baseline . Subjects history development erythema nodosum , characterize desquamate rash , take thalidomide , lenalidomide , pomalidomide similar drug . Concurrent use anticancer agent treatment . Concomitant use CYP3A4 inhibitor ( See Appendix D ) Prior therapy romidepsin , thalidomide pomalidomide Central nervous system meningeal involvement Patients take drug lead significant QT prolongation Known hypersensitivity thalidomide lenalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>